Colorectal cancer in the adjuvant setting: Perspectives on treatment and the role of prognostic factors

Annals of Oncology

Volumn 14, Issue SUPPL. 2, 2003, Pages

  Cascinu, S ^a   Georgoulias, V ^b   Kerr, David ^c   Maughan, T ^d   Labianca, R ^e   Ychou, M ^f  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b University General Hospital of Iraklion   (Greece)

^c RADCLIFFE INFIRMARY   (United Kingdom)

^d VELINDRE CANCER CENTRE   (United Kingdom)

^e OSPEDALI RIUNITI   (Italy)

^f CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CANCER VACCINE; DNA; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; THYMIDYLATE SYNTHASE;

ANGIOGENESIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 18; CLINICAL TRIAL; COLORECTAL CANCER; DNA DETERMINATION; DRUG PREFERENCE; GENETIC MARKER; HETEROZYGOSITY LOSS; HUMAN; METASTASIS; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SIDE EFFECT; STANDARD;

EID: 0038600609     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg725     Document Type: Article

References (33)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics 2001. CA Cancer J Clin 2001; 51: 15-36.
3. Midgley R, Kerr D. Conventional cytotoxic and novel therapeutic concepts in colorectal cancer. Expert Opin Investig Drugs 2001; 10: 1011-1019.
4. Hermaiek P. Pathology of colorectal cancer. In Bleiberg H, Kemeny N, Rougier P, Wilke H. (eds): Colorectal Cancer - A Clinical Guide to Therapy. London. UK: Martin Dunitz 2002; 55-72.
5. Kuwada S, Neklason DW, Burt RW, Biology and molecular genetics of colorectal cancer. In Saltz L. (ed): Colorectal Cancer: Multimodality Management. Totowa, NJ: Humana Press 2002; 3-31.
6. Royce ME, Hoff PM, Pazdur R. Drugs. Progress in colorectal cancer chemotherapy: how far have we come, how far to go? Drugs Aging 2000: 17: 201-216.
7. Moertel CG, Fleming TR, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321-326.
8. O'Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295-300.
9. Peeters M, Haller DG. Therapy for early-stage colorectal cancer. Oncology (Huntingt) 1999; 13: 307-315.
10. Anonymous. Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectat cancer: a randomised trial. QUASAR Collaborative Group. Lancet 2000; 355: 1588-1596.
11. Sargent DJ. Goldberg RM, Jacobson SD et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097.
12. Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and model of prognosis in Dukes' B colon cancer. Gut 2002; 51: 65-69.
13. Anonymous. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators. J Clin Oncol 1999; 17: 1356-1363.
14. Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001; 85: 1437-1443.
15. Cunningham D, Pyrhonen S, James RD et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
16. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
17. Douillard J-Y, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000; 355: 1041-1047.
18. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-914.
19. Tournigand C, Louvet C, Quinaux E et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 2001; 20: 494 (Abstr 1760).
20. Chmielarz A, Kryj M, Wloch I et al. Prognostic factors for the time of occurrence and dynamics of distant metastases and local recurrences after radical treatment in patients with rectal cancer. Med Sci Monit 2001; 7: 1263-1269.
21. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-1206.
22. Hemminki A, Mecklin JP, Jarvinen H et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119: 921-928.
23. Elsaleh H, Joseph D, Grieu Fet al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355: 1745-1750.
24. Ribic C, Sargent DJ, Moore MJ et al. Tumor microsatellite instability (MSI) and the benefit of 5FU based chemotherapy in stage II and III colon cancer: a pooled molecular reanalysis of randomized chemotherapy trials. Proc Am Soc Clin Oncol 2002; 21: 509.
25. Barratt PL, Seymour MT, Stenning SP et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002; 360; 1381-1391.
26. Cascinu S, Graziano F, Valentini M et al. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 2001; 12: 239-244.
27. Edler D, Glimelius B, Hallstrom M et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002; 20: 1721-1728.
28. Corsi DC, Ciaparrone M, Zannoni G et al. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur J Cancer 2002; 38: 527-534.
29. Cascinu S, Ligi M, Graziano F et al. S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma: implications for adjuvant chemotherapy. Cancer 1998; 83: 1081-1085.
30. Liefers GJ, Cleton-Jansen AM, van de Velde CJH et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998; 339: 223-228.
31. Takahashi Y, Tucker SL, Kitadai Y et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132: 541-546.
32. Banner BF, Whitehouse R, Baker SP, Swanson RS. Tumor angiogenesis in stage II colorectal carcinoma: association with survival. Am J Clin Pathol 1998; 109: 733-737.
33. Cascinu S, Staccioli MP, Gasparini G et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000; 6: 2803-2807.